고위험(IMDRF 카테고리 III-IV) SaMD(Software-as-a-Medical Device) 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the high-Risk software as a medical device market size is projected to be USD 22.22 billion in 2025, USD 25.03 billion in 2026, and reach USD 45.41 billion by 2031, growing at a CAGR of 12.65% from 2026 to 2031.

This report is Segmented by Deployment (Cloud-Based, On-Premises, Hybrid), Functionality (Diagnosis Support, and More), Clinical Application (Radiology, Cardiology, and More), End User (Hospitals, Ascs, Specialty Clinics, Diagnostic Imaging Centers, Home Care, Others), IMDRF Risk Class (Category III, Category IV), and Geography (North America, Europe, and More). Forecasts are in Value (USD).

Global High-Risk (IMDRF Category III-IV) Software As A Medical Device (SaMD) Market Trends and Insights

Rising Demand for Clinically Validated AI Diagnostics

Clinical validation now carries more weight than standalone performance claims in procurement across the high-risk Software as a Medical Device (SaMD) market. Buyers require evidence that software performs across real patient populations, multiple sites, and established care pathways after launch. This shift favors vendors that can demonstrate durable outcomes, repeat use, and continuous evidence maintenance, rather than relying on a single authorization milestone. HeartFlow's continued evidence expansion and payer traction show how a validated platform can move from specialized use into broader clinical deployment.

Expanding Reimbursement Support for Digital Diagnostics

Reimbursement support is becoming a more visible growth lever in the high-risk Software as a Medical Device (SaMD) market. Coverage decisions convert clinical interest into repeat purchasing, formal budgeting, and wider provider rollout. HeartFlow Plaque Analysis gained coverage for Aetna plans in January 2026, strengthening the case for AI-supported cardiac assessment in routine care. AdvaMed also urged U.S. policymakers in February 2026 to create a clearer payment pathway for SaMD, showing that reimbursement policy is central to commercialization strategy.

Evidence Burden for Category III and IV Clinical Validation

Evidence requirements remain a key entry barrier in the high-risk Software as a Medical Device (SaMD) market. Category III and IV software requires stronger clinical validation than lower-risk digital tools, especially when outputs influence diagnosis or treatment decisions for serious conditions. NeuroPace's May 2026 FDA approval for ECoG Assistant showed how advanced clinical software remained closely linked to regulated therapeutic ecosystems rather than consumer-style release cycles. These requirements lengthen timelines, increase study costs, and favor companies with established trial networks, hospital relationships, and quality systems, making regional expansion slower and costlier for newer developers even after initial authorization.

Other drivers and restraints analyzed in the detailed report include:

1. Shortage of Specialist Clinicians in Imaging and Monitoring Workflows
2. Faster Regulatory Pathways for Predetermined Change Control Plans
3. Cybersecurity and Software Update Liability Exposure

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Cloud-Based SaMD held 52.56% of 2025 revenue in the deployment segment, reflecting strong enterprise preference for centralized processing across large, multi-site health systems. In the high-risk Software as a Medical Device (SaMD) market, this leadership was driven by the need to manage imaging volumes, audit trails, user permissions, and model performance in one coordinated environment. Large hospital groups favored cloud deployment for remote administration and consistent oversight across facilities using common clinical protocols.

Hybrid SaMD is forecast to expand at 14.93% CAGR through 2031, making it the fastest-growing deployment model as providers balance local control with centralized analytics. On-premises deployment retained relevance in institutions with tighter data residency obligations, stricter internal security rules, or lower tolerance for external data movement. The high-risk Software as a Medical Device (SaMD) market is therefore moving toward federated operating models that keep sensitive inference closer to the patient while preserving centralized update and compliance functions. RapidAI's enterprise platform approach showed why vendors supporting flexible architectures gained traction.

Diagnosis Support accounted for 38.23% of the 2025 high-risk Software as a Medical Device (SaMD) market size by functionality, supported by its broad installed base across radiology, cardiology, and decision-support workflows. Providers adopted this category earlier because it improved interpretation and prioritization without immediately shifting into direct therapy execution. This early adoption gave diagnosis support a stronger procurement position and helped it retain leadership despite rising competition in mature imaging use cases.

Treatment Guidance is forecast to expand at 14.67% CAGR through 2031, making it the fastest-growing functionality in the high-risk Software as a Medical Device (SaMD) market. Growth was strongest where software influenced procedural planning, dose selection, device programming, or other therapy-linked actions in regulated clinical settings. Monitoring and Alerting remained a steady middle cohort, while Triage and Prioritization faced uneven reimbursement and variable workflow adoption. HeartFlow's March 2026 launch of PCI Navigator illustrated the shift from diagnostic assessment to procedural guidance in interventional care.

Complete Report Scope:

• By Deployment
  • Cloud-Based SaMD
  • On-Premises SaMD
  • Hybrid SaMD
• By Functionality
  • Diagnosis Support
  • Monitoring and Alerting
  • Treatment Guidance
  • Triage and Prioritization
• By Clinical Application
  • Radiology
  • Cardiology
  • Neurology
  • Oncology
  • Ophthalmology
  • Gastroenterology
  • Endocrinology
  • Critical Care and Emergency Care
  • Other Clinical Applications
• By End User
  • Hospitals and Health Systems
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Diagnostic Imaging Centers
  • Home Care Settings
  • Others
• By IMDRF Risk Class
  • Category III
  • Category IV
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.88% of 2025 revenue, giving it the largest regional position in the high-risk Software as a Medical Device (SaMD) market. Strong regulatory infrastructure, broad enterprise provider networks, and supportive payer conditions continue to drive adoption. The United States remains the main commercial launch market, while Canada offers a lower-friction adjacency and Mexico provides selective entry through recognition-based pathways.

Europe remained the second-largest regional cluster in the high-risk Software as a Medical Device (SaMD) market. Germany, France, the United Kingdom, and the Netherlands anchor adoption through strong hospital procurement capacity and formal reimbursement review. High-risk software faces a heavier documentation burden under medical device rules and broader AI governance expectations, extending timelines for smaller developers. The United Kingdom can offer a faster secondary launch route, while Spain and Italy show solid clinical interest but fragmented procurement conditions.

Asia-Pacific is forecast to grow at a CAGR of 17.56% through 2031, making it the fastest-growing region in the high-risk Software as a Medical Device (SaMD) market. China, Japan, South Korea, and India are driving expansion through domestic manufacturing scale, maturing regulation, and rising hospital digitization. Japan's 2026 lifecycle framework pointed to stricter post-market expectations for adaptive algorithms, while China continued to favor localized operating models for high-risk AI products. The Middle East and Africa remained at an earlier adoption stage, with GCC health systems moving first, while South America remained nascent, led by Brazil and Argentina, with medium-term opportunities in cardiovascular and oncology-focused care.

1. Aidoc Medical Ltd.
2. AliveCor
3. Apple
4. Butterfly Network, Inc.
5. Carlsmed, Inc.
6. CeriBell, Inc.
7. Dexcom
8. Digital Diagnostics
9. GE HealthCare Technologies Inc.
10. HeartFlow, Inc.
11. Hologic
12. Koninklijke Philips
13. Lunit
14. Medtronic
15. NeuroPace
16. Paige AI, Inc.
17. Qure.ai Technologies Private Limited
18. RapidAI, Inc.
19. Siemens Healthineers
20. Tempus AI, Inc.
21. Viz.ai, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Demand for Clinically Validated AI Diagnostics
  • 4.2.2 Expanding Reimbursement Support for Digital Diagnostics
  • 4.2.3 Shortage of Specialist Clinicians in Imaging and Monitoring Workflows
  • 4.2.4 Faster Regulatory Pathways for Predetermined Change Control Plans
  • 4.2.5 Hospital Digital Transformation and EHR Integration Pressure
  • 4.2.6 Cross-Border Scaling Through Platform-Based Evidence Reuse
• 4.3 Market Restraints
  • 4.3.1 Evidence Burden for Category III and IV Clinical Validation
  • 4.3.2 Cybersecurity and Software Update Liability Exposure
  • 4.3.3 Data Access Fragmentation Across Health Systems
  • 4.3.4 Low Interoperability With Legacy Clinical IT Infrastructure
• 4.4 Value/Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Deployment
  • 5.1.1 Cloud-Based SaMD
  • 5.1.2 On-Premises SaMD
  • 5.1.3 Hybrid SaMD
• 5.2 By Functionality
  • 5.2.1 Diagnosis Support
  • 5.2.2 Monitoring and Alerting
  • 5.2.3 Treatment Guidance
  • 5.2.4 Triage and Prioritization
• 5.3 By Clinical Application
  • 5.3.1 Radiology
  • 5.3.2 Cardiology
  • 5.3.3 Neurology
  • 5.3.4 Oncology
  • 5.3.5 Ophthalmology
  • 5.3.6 Gastroenterology
  • 5.3.7 Endocrinology
  • 5.3.8 Critical Care and Emergency Care
  • 5.3.9 Other Clinical Applications
• 5.4 By End User
  • 5.4.1 Hospitals and Health Systems
  • 5.4.2 Ambulatory Surgical Centers
  • 5.4.3 Specialty Clinics
  • 5.4.4 Diagnostic Imaging Centers
  • 5.4.5 Home Care Settings
  • 5.4.6 Others
• 5.5 By IMDRF Risk Class
  • 5.5.1 Category III
  • 5.5.2 Category IV
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Aidoc Medical Ltd.
  • 6.3.2 AliveCor, Inc.
  • 6.3.3 Apple Inc.
  • 6.3.4 Butterfly Network, Inc.
  • 6.3.5 Carlsmed, Inc.
  • 6.3.6 CeriBell, Inc.
  • 6.3.7 DexCom, Inc.
  • 6.3.8 Digital Diagnostics Inc.
  • 6.3.9 GE HealthCare Technologies Inc.
  • 6.3.10 HeartFlow, Inc.
  • 6.3.11 Hologic, Inc.
  • 6.3.12 Koninklijke Philips N.V.
  • 6.3.13 Lunit Inc.
  • 6.3.14 Medtronic plc
  • 6.3.15 NeuroPace, Inc.
  • 6.3.16 Paige AI, Inc.
  • 6.3.17 Qure.ai Technologies Private Limited
  • 6.3.18 RapidAI, Inc.
  • 6.3.19 Siemens Healthineers AG
  • 6.3.20 Tempus AI, Inc.
  • 6.3.21 Viz.ai, Inc.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment